Novel polypeptide, fusion polypeptide, and antibiotics against gram-negative bacteria containing the same
Patent Information
- Application Number
- JP2022570284
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-02-10
- Filing Date
- 2021-05-20
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-05-20
Smart Images

Figure 0007584162000011 
Figure 0007584162000012 
Figure 0007584162000013
Abstract
Description
[Technical field]
[0001] The present invention provides a novel polypeptide, a fusion polypeptide containing the polypeptide, and its use as an antibiotic. More specifically, the present invention provides a novel polypeptide derived from a bacteriophage, a fusion polypeptide containing the polypeptide and Cecropin A, and an antibiotic against Gram-negative bacteria containing the polypeptide and / or the fusion protein. [Background technology]
[0002] Bacteriophage refers to a bacterium-specific virus that infects a specific bacterium and suppresses or inhibits the growth of the infected bacterium. Bacteriophage infect the host bacterium and then grow within the bacterial cell. After growth, the progeny bacteriophage emerge from the bacterium and destroy the cell wall of the host bacterium using endolysin, a bacteriophage protein, to kill the bacterium. Therefore, substances with bacteriophage endolysin activity can be usefully applied as antibiotic candidates.
[0003] Recently, antibiotic-resistant bacteria are rapidly increasing, and multi-drug resistant bacteria that cannot be treated with any antibiotic are on the rise. In particular, Pseudomonas aeruginosa, a gram-negative bacterium, is one of the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) bacteria for which the development of new treatment methods is urgently needed worldwide, and Escherichia coli is a bacterium involved in various infectious diseases. Therefore, the development of a treatment method that is differentiated from existing antibiotics is required. Summary of the Invention
[0004] Problem to be solved by the invention One embodiment of the present invention provides a novel polypeptide. The polypeptide may comprise the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6. The polypeptide may be derived from a bacteriophage or a variant thereof. The polypeptide may have endolysin activity.
[0005] Other embodiments provide a polynucleotide encoding the polypeptide. The polynucleotide may comprise the nucleic acid sequence of SEQ ID NO:2 or SEQ ID NO:7.
[0006] Another embodiment provides a recombinant vector comprising the polynucleotide, the recombinant vector being used as an expression vector.
[0007] Other embodiments provide a recombinant cell comprising the polynucleotide or a recombinant vector comprising the same. The recombinant cell may be for expression of the polynucleotide.
[0008] Other embodiments provide a bacteriophage comprising the polypeptide of SEQ ID NO:1, a polynucleotide encoding same (e.g., SEQ ID NO:2), or a combination thereof. The genome of the bacteriophage can comprise the nucleic acid sequence of SEQ ID NO:5.
[0009] Another embodiment provides a novel fusion polypeptide. The fusion polypeptide may include Cecropin A and an endolysin. The Cecropin A may be, for example, the amino acid sequence of SEQ ID NO: 8. The endolysin is derived from a bacteriophage or a variant thereof, and may be, for example, the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6. In the fusion polypeptide, the Cecropin A (for example, SEQ ID NO: 8) and the endolysin (for example, SEQ ID NO: 1 or SEQ ID NO: 6) may be linked by a linker in any order, or directly linked without a linker. In one embodiment, the fusion polypeptide may be the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 13.
[0010] Another embodiment provides a polynucleotide encoding the fusion polypeptide. The polynucleotide may comprise the nucleic acid sequence of SEQ ID NO:11 or SEQ ID NO:14.
[0011] Another embodiment provides a recombinant vector comprising the polynucleotide, the recombinant vector being used as an expression vector.
[0012] Other embodiments provide a recombinant cell comprising the polynucleotide or a recombinant vector comprising the same. The recombinant cell may be for expression of the polynucleotide.
[0013] Another embodiment is (1) one or more polypeptides selected from SEQ ID NO:1 and SEQ ID NO:6; (2) a fusion polypeptide comprising the polypeptide and cecropin A (e.g., SEQ ID NO: 10 or SEQ ID NO: 13), or a combination thereof; (3) A polynucleotide encoding the polypeptide of (1) above. (4) A polynucleotide encoding the fusion polypeptide of (2) above. (5) A recombinant vector comprising the polynucleotide of (3), the polynucleotide of (4), or a combination thereof. (6) A recombinant cell comprising the polynucleotide of (3), the polynucleotide of (4), or a combination thereof, or a recombinant vector comprising the polynucleotide; and (7) Provided is an antibiotic comprising one or more selected from the group consisting of a bacteriophage comprising a polypeptide of SEQ ID NO:1, a polynucleotide encoding the same, or a combination thereof.
[0014] The antibiotic may have an antibiotic effect against gram-negative bacteria.
[0015] The antibiotic (first antibiotic) according to the present invention has the advantage that, when used in combination with another antibiotic (second antibiotic), it can exert a synergistic effect due to its own antibiotic effect and can exert an excellent antibiotic effect even when the second antibiotic is used at a low concentration. Therefore, it is possible to reduce side effects such as toxicity (e.g., nephrotoxicity, hepatotoxicity, etc.) caused by the use of high concentrations of antibiotics. In addition, it is possible to suppress the emergence of drug-resistant bacteria caused by the combined use of antibiotics with different mechanisms.
[0016] Therefore, one embodiment is (a) one or more selected from the group consisting of (1) one or more polypeptides selected from SEQ ID NO:1 and SEQ ID NO:6, (2) a fusion polypeptide comprising the polypeptide and cecropin A (e.g., SEQ ID NO:10 or SEQ ID NO:13), or a combination thereof, (3) a polynucleotide encoding the polypeptide of (1), (4) a polynucleotide encoding the fusion polypeptide of (2), (5) a recombinant vector comprising the polynucleotide of (3), the polynucleotide of (4), or a combination thereof, (6) a recombinant cell comprising the polynucleotide of (3), the polynucleotide of (4), or a combination thereof or a recombinant vector comprising the polynucleotide, and (7) a bacteriophage comprising the polypeptide of SEQ ID NO:1, a polynucleotide encoding the polypeptide, or a combination thereof; and (b) Providing a combination antibiotic that includes an antibiotic (e.g., a polymyxin antibiotic such as polymyxin B and / or colistin).
[0017] Another embodiment provides a pharmaceutical composition for preventing and / or treating infection with or a disease caused by Pseudomonas bacteria, comprising the antibiotic or a combination of antibiotics as an active ingredient.Another embodiment provides a method for preventing or treating infection with or a disease caused by Pseudomonas bacteria, comprising administering a pharmacologic effective amount of the antibiotic or a combination of antibiotics to a subject in need of prevention and / or treatment of infection with or a disease caused by Pseudomonas bacteria.
[0018] Another embodiment provides a feed additive comprising said antibiotic or combination of antibiotics as an active ingredient.
[0019] Another embodiment provides a disinfectant comprising said antibiotic or combination of antibiotics as active ingredients.
[0020] Another embodiment provides a method of disinfection comprising the step of applying said antibiotic or combination of antibiotics to a subject in need of disinfection.
[0021] Other embodiments provide cleaning agents that contain said antibiotic or combination of antibiotics as active ingredients.
[0022] Another embodiment provides a method of cleansing comprising applying said antibiotic or combination of antibiotics to a subject in need of cleansing.
[0023] Means for solving the problem Bacteriophages, which grow using bacteria as hosts and are used in natural antibiotics, invade bacteria and complete their growth inside, and then release the completed phage particles outside the bacteria. At this time, endolysin is an enzyme that attacks and breaks down the bacterial cell wall, creating a passageway for release to the outside. All bacteriophages have such endolysin genes in their genomes, and use the endolysin protein expressed during growth. Bacteriophages that grow using bacteria as hosts and endolysins derived from bacteriophages that have the ability to break down cell walls are used in natural antibiotics.
[0024] In the case of gram-positive bacteria, the cell wall is located at the outermost wall, so when endolysin is added from the outside, the cell wall is immediately attacked and decomposed. In contrast, in the case of gram-negative bacteria, the outer cell membrane is located at the outermost wall, and the cell wall is located inside it, so even if endolysin is added from the outside, it must first pass through the outer cell membrane before it can come into contact with the cell wall. Therefore, it is known that endolysin is basically ineffective against gram-negative bacteria. The polypeptides having endolysin activity provided in this specification are characterized by having the effect of killing gram-negative bacteria.
[0025] Meanwhile, the Cecropin A is a peptide having antibacterial activity, which has the effect of dissolving bacterial membranes.
[0026] In the present specification, a novel polypeptide or a fusion polypeptide in which cecropin A is fused to a novel polypeptide has been demonstrated to have antibiotic effects superior to existing endolysins, and a polypeptide having endolysin activity, as well as antibiotics and / or related uses thereof, are provided. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0027] The present invention will now be described in more detail. Definition of Terms As used herein, a polynucleotide (commonly used with "gene") or a polypeptide (commonly used with "protein") "comprises a specific nucleic acid sequence or amino acid sequence" or "consists of a specific nucleic acid sequence or amino acid sequence" means that the polynucleotide or polypeptide necessarily contains the specific nucleic acid sequence or amino acid sequence, and is interpreted as including "substantially equivalent sequences" in which mutations (deletions, substitutions, modifications, and / or additions) have been added to the specific nucleic acid sequence or amino acid sequence to the extent that the original function and / or intended function of the polynucleotide or polypeptide is maintained (or the mutations are not excluded).
[0028] In one embodiment, a polynucleotide or polypeptide "comprises a particular nucleic acid or amino acid sequence" or "consists of or is expressed by a particular nucleic acid or amino acid sequence" means that the polynucleotide or polypeptide (i) necessarily contains the particular nucleic acid or amino acid sequence, or (ii) consists of or necessarily contains an amino acid sequence that has 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the particular nucleic acid or amino acid sequence, and maintains its original and / or intended function. As used herein, the original function is an endolysin enzyme function (e.g., peptidoglycan hydrolysis activity), cecropin A activity (e.g., cell membrane lytic activity), and / or antibiotic activity (in the case of an amino acid sequence), or a function encoding a protein having endolysin enzyme function, cecropin A activity, and / or antibiotic activity (in the case of a nucleic acid sequence), and the desired function means antibiotic activity against gram-negative bacteria, such as Pseudomonas bacteria, e.g., Pseudomonas aeruginosa.
[0029] In this specification, the term "identity" refers to the degree of identity to a given nucleic acid sequence or amino acid sequence, and is expressed as a percentage (%). In the case of identity to a nucleic acid sequence, it can be determined, for example, by using the literature algorithm BLAST (reference: Karlin and Altschμl, Pro. Natl. Acad. Sci. USA, 90, 5873, 1993) or Pearson's FASTA (reference: Methods Enzymol., 183, 63, 1990). Based on this algorithm BLAST, a program called BLASTN or BLASTX has been developed (reference: http: / / www.ncbi.nlm.nih.gov).
[0030] The proteins or polypeptides provided herein may be isolated and / or purified from nature, or may be recombinantly or chemically synthesized. When the amino acid sequence of a protein or polypeptide provided herein contains a methionine (Met, M) or Met-Ala-Ser (MAS) sequence as the first amino acid residue from the N-terminus, the protein or polypeptide may be recombinantly produced, and the methionine at the first amino acid position from the N-terminus may be encoded by a start codon. Therefore, when the amino acid sequence of a protein or polypeptide provided herein contains a methionine at the N-terminus by recombinant production, when the protein or polypeptide is obtained by another method (e.g., chemical synthesis or isolation from nature), it can be interpreted as including an amino acid sequence starting from the second amino acid residue excluding the first methionine from the N-terminus by the recombinant production, or an amino acid sequence starting from the next amino acid residue (e.g., the fourth amino acid residue) of the MAS sequence.
[0031] Novel polypeptides and polynucleotides encoding same One embodiment provides a novel polypeptide. The polypeptide may comprise the amino acid sequence of SEQ ID NO:1. The polypeptide may be derived from a bacteriophage. The polypeptide has endolysin activity derived from a bacteriophage. The polypeptide may have a molecular weight of about 28 kDa (28 kDa±2).
[0032] In other embodiments, the polypeptide may comprise the amino acid sequence of SEQ ID NO: 6. The polypeptide is a bacteriophage-derived endolysin mutant and has superior endolysin and / or antibiotic activity compared to bacteriophage-derived endolysins. The polypeptide may have a molecular weight of about 28 kDa (28 kDa ± 2). The polypeptide may be produced recombinantly or synthetically (e.g., chemically synthesized).
[0033] Other embodiments provide a polynucleotide encoding the polypeptide. The polynucleotide may comprise the nucleic acid sequence of SEQ ID NO:2 or SEQ ID NO:7.
[0034] Endolysin refers to a bacteriophage-encoded peptidoglycan hydrolase. Endolysins are synthesized during late gene expression in the lytic cycle of bacteriophage growth and mediate the release of progeny virions from infected cells by degradation of bacterial peptidoglycan. In terms of enzymatic activity, endolysins may have one or more activities usually selected from the group consisting of glucosaminidase, muramidase (a type of lysozyme), transglycosylase, amidase, endopeptidase, etc.
[0035] In this specification, unless otherwise specified, a polypeptide having endolysin activity as a polypeptide "comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6" or "consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6" is (1) a polypeptide consisting of or necessarily comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6, and / or (2) an amino acid sequence having 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6 (for example, an amino acid sequence having 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6) "A polypeptide" means a polypeptide that consists of or necessarily contains an amino acid sequence having 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the amino acid sequence of (A) of the polypeptide of the present invention and that has (maintains) endolysin enzyme function (e.g., peptidoglycan hydrolysis activity) and / or antibiotic activity against bacteria of the genus Pseudomonas, e.g., Pseudomonas aeruginosa.
[0036] In addition, unless otherwise specified in this specification, a polynucleotide encoding a polypeptide "comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6" or "consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6" is (a) a polynucleotide encoding a polypeptide consisting of or necessarily comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:6, and / or (b) an amino acid sequence having 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6 (e.g., an amino acid sequence having 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more identity to the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence of SEQ ID NO: 6) 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity) and encoding a polypeptide that has (maintains) an endolysin enzymatic function (e.g., peptidoglycan hydrolysis activity) and / or antibiotic activity against Pseudomonas bacteria, e.g., Pseudomonas aeruginosa, and / or (c) means a polynucleotide "comprising" or "consisting of" the nucleic acid sequence of SEQ ID NO:2 or SEQ ID NO:7, A polynucleotide "comprising the nucleic acid sequence of SEQ ID NO:2 or SEQ ID NO:7" or "consisting of the nucleic acid sequence of SEQ ID NO:2 or SEQ ID NO:7" is (d) a polynucleotide consisting of or necessarily comprising the nucleic acid sequence of SEQ ID NO: 2 or SEQ ID NO: 7; or (e) a polynucleotide that consists of or necessarily comprises a nucleic acid sequence having 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the nucleic acid sequence of SEQ ID NO:2 or SEQ ID NO:7 (e.g., a nucleic acid sequence having 99.7% or more, 99.8% or more, or 99.9% or more identity to the nucleic acid sequence of SEQ ID NO:2 or a nucleic acid sequence having 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the nucleic acid sequence of SEQ ID NO:7) and encodes a polypeptide that has (maintains) an endolysin enzyme function (e.g., peptidoglycan hydrolysis activity) and / or antibiotic activity against Gram-negative bacteria.
[0037] Fusion polypeptides and polynucleotides encoding same Another embodiment provides a novel fusion polypeptide, which may comprise cecropin A and an endolysin. The Cecropin A is derived from the butterfly Hyalophora cecropia and may, for example, have the amino acid sequence of SEQ ID NO: 8. The endolysin is derived from a bacteriophage or a variant thereof and may, for example, have the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6.
[0038] In the fusion polypeptide, the cecropin A (e.g., SEQ ID NO: 8) and the endolysin (e.g., SEQ ID NO: 1 or SEQ ID NO: 6) are linked in any order, i.e., in the fusion polypeptide, the cecropin A and the endolysin are linked in the order of cecropin A and endolysin or endolysin and cecropin A from the N-terminus, e.g., cecropin A and endolysin.
[0039] Also, the Cecropin A (eg, SEQ ID NO: 8) and the endolysin (eg, SEQ ID NO: 1 or SEQ ID NO: 6) are linked by a peptide linker or directly without a linker.
[0040] In one embodiment, the fusion polypeptide may have the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:13.
[0041] The fusion polypeptide has superior antibiotic activity and / or superior outer membrane permeabilization activity against Gram-negative bacteria compared to endolysin or cecropin A. The fusion polypeptide can have a molecular weight of about 34 kDa (e.g., 34 kDa±3). The fusion polypeptide or endolysin and cecropin A are produced recombinantly or synthetically (e.g., chemically synthesized).
[0042] Another embodiment provides a polynucleotide encoding the fusion polypeptide. The polynucleotide may comprise the nucleic acid sequence of SEQ ID NO:11 or SEQ ID NO:14.
[0043] The novel polypeptides provided herein (e.g., SEQ ID NO:1 or SEQ ID NO:6) have endolysin activity. Endolysin refers to a bacteriophage-encoded peptidoglycan hydrolase. Endolysins are synthesized during late gene expression in the lytic cycle of bacteriophage proliferation and mediate the release of progeny virions from infected cells by degradation of bacterial peptidoglycan. In terms of enzymatic activity, endolysins usually have one or more activities selected from the group consisting of glucosaminidase, muramidase (a type of lysozyme), transglycosylase, amidase, endopeptidase, etc.
[0044] In this specification, unless otherwise specified, the fusion polypeptide is (1) a polypeptide consisting of or necessarily comprising SEQ ID NO:8 or an amino acid sequence having 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the amino acid sequence of SEQ ID NO:8, and having (maintaining) cecropin A activity; and (2) SEQ ID NO: 1, SEQ ID NO: 6, or an amino acid sequence having 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to these amino acid sequences (e.g., an amino acid sequence having 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more identity to the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the amino acid sequence of SEQ ID NO: 6), or may contain polypeptides having (maintaining) endolysin activity in any order (e.g., in order from the N-terminus).
[0045] In one embodiment, the fusion polypeptide comprises: a polypeptide which necessarily comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 13, and / or This means a polypeptide that consists of or necessarily contains an amino acid sequence that has 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 13, and that has (maintains) antibiotic activity against gram-negative bacteria.
[0046] In addition, unless otherwise specified, in the present specification, a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 is (a) a polynucleotide encoding a polypeptide consisting of or comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 13, and / or (b) a polynucleotide encoding a polypeptide that consists of or necessarily comprises an amino acid sequence having 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 13 and has (maintains) antibiotic activity against Gram-negative bacteria; and / or (c) a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 11 or SEQ ID NO: 14, A polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 11 or SEQ ID NO: 14 (d) a polynucleotide consisting of or comprising the nucleic acid sequence of SEQ ID NO:11 or SEQ ID NO:14, and / or (e) means a polynucleotide that consists of or necessarily comprises a nucleic acid sequence having 96% or more, 96.5% or more, 97% or more, 97.5% or more, 98% or more, 98.5% or more, 99% or more, 99.5% or more, or 99.9% or more identity to the nucleic acid sequence of SEQ ID NO:11 or SEQ ID NO:14 and encodes a polypeptide that has (maintains) antibiotic activity against Gram-negative bacteria.
[0047] In the fusion polypeptide provided herein, cecropin A and endolysin are linked by a peptide linker or directly linked without a peptide linker. The peptide linker is a polypeptide consisting of any amino acid of 1 to 100, 2 to 50, 1 to 30, 2 to 20, or 2 to 10, and the type of amino acid contained therein is not limited. The peptide linker may contain, for example, one or more amino acid residues selected from the group consisting of Gly, Ser, Leu, Gln, Asn, Thr, and Ala. Amino acid sequences suitable for peptide linkers are known in the art. Meanwhile, the length of the linker can be determined in various ways within a range that does not affect the structure and / or function of the fusion protein. For example, the peptide linker may contain a total of 1 to 100, 2 to 50, 1 to 30, 2 to 20, or 2 to 10 of one or more selected from the group consisting of Gly, Ser, Leu, Gln, Asn, Thr, and Ala. In one embodiment, the peptide linker is GSGSGS (SEQ ID NO: 12), (G) 4~10 (For example, GGGGGG, GGGGGGGG, etc.), (GGGGS) 1~5 (For example, (GGGGS)1), (EAAAK) 1-5 (For example, (EAAAK)3, (EAAAK)5, etc.), (EAAAK)4(GGGGS)1, etc., but are not limited to these.
[0048] Recombinant vectors and recombinant cells Another embodiment provides a recombinant vector comprising a polynucleotide encoding the above-described polypeptide (a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:6) or the above-described fusion polypeptide (e.g., SEQ ID NO:10 or SEQ ID NO:13). The recombinant vector can be used as an expression vector.
[0049] Another embodiment provides a method for producing said polypeptide or said fusion polypeptide, comprising the step of expressing said polypeptide or said fusion polypeptide in a suitable host cell. The step of expressing said polypeptide or said fusion polypeptide in a suitable host cell can be carried out by culturing a recombinant cell comprising said polynucleotide or a recombinant vector comprising same. The method for producing said endolysin may further comprise the step of isolating and / or purifying the expressed endolysin after said expression step.
[0050] The polynucleotide or vector can be introduced into a host cell by appropriately selecting a known transformation method by a person skilled in the art. In the present specification, the term "transformation" means introducing a vector containing a polynucleotide encoding the polypeptide into a host cell to express the polypeptide encoded by the polynucleotide in the host cell. The transformed polynucleotide may include all polynucleotides, regardless of whether they are inserted into the chromosome of the host cell or extrachromosomally located, as long as they can be expressed in the host cell. The polynucleotide is not limited in its form of introduction, so long as it is introduced into the host cell and expressed. For example, the polynucleotide is introduced into the host cell in the form of an expression cassette, which is a genetic structure containing all elements necessary for self-expression. The expression cassette may usually contain expression regulators such as a promoter, a transcription termination signal, a ribosome binding site, and / or a translation termination signal operably linked to the polynucleotide. The expression cassette may be in the form of a self-replicating expression vector. The polynucleotide is also introduced into the host cell in its own form and operably linked to a sequence required for expression in the host cell. The term "operably linked" means that the polynucleotide is functionally linked to an expression control element (e.g., a promoter) so as to be capable of regulating the transcription of the polynucleotide (e.g., initiating transcription). Operable linkage can be achieved using recombinant gene techniques known in the art.
[0051] The method for transforming the polynucleotide into the host cell can be any method for introducing a nucleic acid into a cell (microorganism), and can be appropriately selected from transformation techniques known in the art according to the host cell. The known transformation methods include, but are not limited to, electroporation, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, microinjection, polyethylene glycol (PEG) precipitation (polyethylene glycol-mediated uptake), DEAE-dextran method, cationic liposome method, lipofection, lithium acetate-DMSO method, etc.
[0052] As used herein, the term "vector" refers to a DNA construct containing a polynucleotide sequence operably linked to a suitable regulatory sequence to enable expression of a target protein in a suitable host. The regulatory sequence may include a promoter for initiating transcription, an optional operator sequence for regulating transcription, a sequence encoding a suitable mRNA ribosome binding site, and / or a sequence for regulating the termination of transcription and / or translation. When transformed into a suitable host cell, the vector is expressed independently of the genome of the host cell or is integrated into the genome of the host cell itself.
[0053] The vector used in the present invention is not particularly limited as long as it can be replicated in a host cell, and can be selected from all commonly used vectors. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, the phage vector or cosmid vector can be pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A, and the plasmid vector can be pBR, pUC, pBluescriptII, pGEM, pTZ, pCL, and pET. Specific examples include, but are not limited to, pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, and pCC1BAC vectors.
[0054] The vector may further include a selection marker for confirming whether or not the vector has been inserted into the chromosome. The selection marker is used to select cells transformed with the vector, i.e., to confirm whether or not the polynucleotide has been inserted, and is selected from genes that confer selectable phenotypes such as drug resistance, auxotrophy, resistance to cytotoxic agents, or expression of surface proteins. In an environment treated with a selective agent, only cells expressing the selection marker survive or show a different phenotype, so that transformed cells can be selected.
[0055] The polypeptides provided herein may not be naturally derived, but may be recombinantly or chemically synthesized. When the polypeptides are recombinantly produced, they may be in a form to which a normal signal peptide, cleavage site, tag, etc. is bound for purification. Thus, as a non-limiting example, the polypeptides provided herein may be in a form further comprising one or more selected from the group consisting of a signal peptide, cleavage site, tag (e.g., His tag, GST (glutathione-s-transferase) tag, MBP (maltose binding protein) tag, etc.) that can be normally used in the recombinant production process of proteins, or in a purified form in which these have been removed.
[0056] antibiotics Another embodiment is (1) one or more polypeptides selected from SEQ ID NO:1 and SEQ ID NO:6; (2) a fusion polypeptide comprising the polypeptide and cecropin A (e.g., SEQ ID NO: 10), or a combination thereof; (3) A polynucleotide encoding the polypeptide of (1) above. (4) A polynucleotide encoding the fusion polypeptide of (2) above. (5) A recombinant vector comprising the polynucleotide of (3), the polynucleotide of (4), or a combination thereof. (6) A recombinant cell comprising the polynucleotide of (3), the polynucleotide of (4), or a combination thereof, or a recombinant vector comprising the polynucleotide; and (7) Provided is an antibiotic comprising one or more selected from the group consisting of a bacteriophage comprising a polypeptide of SEQ ID NO:1, a polynucleotide encoding the same, or a combination thereof.
[0057] The antibiotic has an antibiotic effect against gram-negative bacteria. The gram-negative bacteria may be one or more (e.g., one, two, three, four, or five) selected from the group consisting of Pseudomonas bacteria, Acinetobacter bacteria, Escherichia bacteria, Enterobacter bacteria, Klebsiella bacteria, and the like. For example, the Pseudomonas bacteria may be Pseudomonas aeruginosa, the Acinetobacter bacteria may be Acinetobacter baumannii, the Escherichia bacteria may be Escherichia coli, the Enterobacter bacteria may be Enterobacter aerogenes, and the Klebsiella bacteria may be Klebsiella pneumoniae, but are not limited thereto.
[0058] The antibiotics provided herein may further include another antibiotic (a second antibiotic) in addition to one or more selected from the group consisting of the above-mentioned polypeptide (a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:6) or the fusion polypeptide, a polynucleotide encoding the polypeptide or the fusion polypeptide, a recombinant vector comprising the polynucleotide, and a recombinant cell comprising the polynucleotide or a recombinant vector comprising the same (hereinafter referred to as a first antibiotic).
[0059] The second antibiotic may be one or more selected from commonly used antibiotics, such as antibiotics having antibiotic activity against Gram-negative bacteria. In one embodiment, the second antibiotic may be a polymyxin antibiotic, such as, but not limited to, polymyxin B, colistin, or a combination thereof.
[0060] In this way, by using an antibiotic (first antibiotic) in combination with another antibiotic (second antibiotic), there is an advantage that a synergistic effect due to the antibiotic effect of the first antibiotic itself and an excellent antibiotic effect can be exhibited even at a low concentration of the second antibiotic. Therefore, side effects such as toxicity (e.g., kidney toxicity, liver toxicity, etc.) caused by the use of high concentrations of antibiotics can be reduced. In addition, the emergence of drug-resistant bacteria caused by the combined use of antibiotics with different mechanisms can be suppressed.
[0061] Therefore, one embodiment is (a) one or more selected from the group consisting of (1) one or more polypeptides selected from SEQ ID NO: 1 and SEQ ID NO: 6, (2) a fusion polypeptide containing the polypeptide and cecropin A (e.g., SEQ ID NO: 10), or a combination thereof, (3) a polynucleotide encoding the polypeptide of (1), (4) a polynucleotide encoding the fusion polypeptide of (2), (5) a recombinant vector containing the polynucleotide of (3), the polynucleotide of (4), or a combination thereof, (6) a recombinant cell containing the polynucleotide of (3), the polynucleotide of (4), or a combination thereof or a recombinant vector containing the polynucleotide, and (7) a bacteriophage containing the polypeptide of SEQ ID NO: 1, a polynucleotide encoding the polypeptide, or a combination thereof; and (b) providing a combination antibiotic comprising an antibiotic (e.g., a polymyxin antibiotic such as polymyxin B, colistin, or a combination thereof);
[0062] As used herein, the term "antibiotic" encompasses all forms of preparations having growth inhibitory and / or bactericidal activity against gram-negative bacteria, and unless otherwise specified, can be used interchangeably with antibacterial agents, preservatives, bactericides, etc.
[0063] Pharmaceutical Compositions Another embodiment provides a pharmaceutical composition for preventing and / or treating infection with or a disease caused by a gram-negative bacterium, comprising the antibiotic or a combination of antibiotics as an active ingredient.
[0064] Another embodiment provides a method for preventing or treating infection with or a disease caused by a gram-negative bacterium, comprising administering a pharmacologic effective amount of the antibiotic or a combination of antibiotics to a subject in need of the prevention and / or treatment of infection with or a disease caused by a gram-negative bacterium. The method for preventing or treating may further comprise, prior to the administering step, identifying a subject in need of the prevention or treatment of infection with or a disease caused by a gram-negative bacterium. The gram-negative bacterium is as described above.
[0065] The disease caused by the gram-negative bacteria is selected from all diseases caused by infection with gram-negative bacteria, for example, diseases caused by Pseudomonas bacteria such as skin infection, bedsore, pneumonia, bacteremia, sepsis, endocarditis, meningitis, otitis externa, otitis media, keratitis, osteomyelitis, enteritis, peritonitis, and cystic fibrosis; diseases caused by Acinetobacter bacteria such as skin infection, pneumonia, bacteremia, and sepsis; and diseases caused by Escherichia bacteria such as enteritis, Crohn's disease, ulcerative colitis, bacterial dysentery, urinary tract infection, skin infection, bacteremia, and sepsis, but is not limited to these.
[0066] As used herein, the term "pharmaceutical effective amount" refers to the content or dosage of an active ingredient that provides a desired effect. The content or dosage of an active ingredient in the pharmaceutical composition can be formulated in various ways depending on factors such as formulation method, administration method, age, weight, sex, pathological condition, diet, administration time, administration interval, administration route, excretion rate, and reaction sensitivity. For example, when the active ingredient is a polypeptide, the dosage per dose may be in the range of 0.001 to 1000 mg / kg, 0.01 to 100 mg / kg, 0.01 to 50 mg / kg, 0.01 to 20 mg / kg, 0.01 to 10 mg / kg, 0.01 to 5 mg / kg, 0.1 to 100 mg / kg, 0.1 to 50 mg / kg, 0.1 to 20 mg / kg, 0.1 to 10 mg / kg, 0.1 to 5 mg / kg, 1 to 100 mg / kg, 1 to 50 mg / kg, 1 to 20 mg / kg, 1 to 10 mg / kg, or 1 to 5 mg / kg, but is not limited to these.
[0067] In other embodiments, the content of the active ingredient in the pharmaceutical composition is, based on the weight of the total pharmaceutical composition, 0.01% to 99.9% by weight, 0.01% to 90% by weight, 0.01% to 80% by weight, 0.01% to 70% by weight, 0.01% to 60% by weight, 0.01% to 50% by weight, 0.01% to 40% by weight, 0.01% to 30% by weight, 1% to 99.9% by weight, 1% to 90% by weight, 1% to 80% by weight, 1% to 70% by weight, 1% to 60% by weight, 1% to 50% by weight, 1% to 100% by weight, 1% to 200% by weight, 1% to 200% by weight, 1% to 300% by weight, 1% to 99.9% by weight, 1% to 90% by weight, 1% to 80% by weight, 1% to 70% by weight, 1% to 60% by weight, 1% to 50% by weight, 1% to 100% by weight, 1% to 200% by weight, 1% to 300% by weight, 1% to 99.9% by weight, The amount of the carboxylic acid may be, but is not limited to, 10% to 40% by weight, 1% to 30% by weight, 5% to 99.9% by weight, 5% to 90% by weight, 5% to 80% by weight, 5% to 70% by weight, 5% to 60% by weight, 5% to 50% by weight, 5% to 40% by weight, 5% to 30% by weight, 10% to 99.9% by weight, 10% to 90% by weight, 10% to 80% by weight, 10% to 70% by weight, 10% to 60% by weight, 10% to 50% by weight, 10% to 40% by weight, or 10% to 30% by weight.
[0068] In addition, the pharmaceutical composition may further include a pharma- ceutically acceptable carrier in addition to the active ingredient. The pharma- ceutically acceptable carrier means a carrier that is commonly used in the formulation of drugs including proteins, nucleic acids, or cells, and does not stimulate living organisms and does not inhibit the biological activity and / or properties of the active ingredient. For example, the carrier may be one or more selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, but is not limited thereto. The pharmaceutical composition may also further include one or more selected from the group consisting of diluents, excipients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, and the like that are commonly used in the manufacture of pharmaceutical compositions.
[0069] The subjects to which the pharmaceutical composition is administered may be one or more mammals selected from the group consisting of primates such as humans and monkeys, rodents such as mice and rats, livestock such as dogs, cats, pigs, cows, horses, sheep and goats, and poultry such as chickens, ducks, geese, pheasants, quails and turkeys, or cells, tissues, or cultures thereof derived therefrom.
[0070] The pharmaceutical composition may be administered orally or parenterally, or by contacting cells, tissues, or body fluids. Specifically, parenteral administration may be subcutaneous, intramuscular, intravenous, peritoneal, intradermal, topical, intranasal, pulmonary, and rectal. When administered orally, proteins or peptides are digested, so oral compositions must be formulated to coat the active agent or protect it from digestion in the stomach. In the case of intranasal administration, the pharmaceutical composition may be diluted and administered by nasal spray to be absorbed into the nasal cavity by a spray or spray system, and examples of nasal spray or respiratory dosage forms for the nasal spray include aerosols.
[0071] In addition, the pharmaceutical composition may be formulated in the form of a solution in an oil or aqueous medium, an injection, a suspension, a syrup, an emulsion, an ointment, a patch, an extract, a powder, a powder, a granule, a tablet, a capsule, or an aerosol, and may further contain a dispersant or a stabilizer for formulation.
[0072] Another embodiment provides a feed additive comprising said antibiotic or combination of antibiotics as an active ingredient.
[0073] Another embodiment provides a feed comprising the feed additive composition.
[0074] The feed may be prepared by mixing the antibiotic or the combination antibiotic with the feed, or by adding the antibiotic or the combination antibiotic to the feed during the preparation of the feed.
[0075] The antibiotic or the combined antibiotic in the feed may be in liquid or dry form, for example, in dry powder form. The antibiotic may be present in an amount of 0.005-10% by weight, 0.05-10% by weight, 0.1-10% by weight, 0.005-5% by weight, 0.05-5% by weight, 0.1-5% by weight, 0.005-2% by weight, 0.05-2% by weight, or 0.1-2% by weight based on the total weight of the feed, but is not limited thereto. In addition, the feed may further contain, in addition to the antibiotic or the combined antibiotic, a conventional additive capable of enhancing the shelf life of the feed.
[0076] In the present specification, the feed to which the antibiotic or the combined antibiotic can be added is selected from the group consisting of commercially available feed, grains, roots and fruits, food processing by-products, algae, dietary fiber, pharmaceutical by-products, oils and fats, starches, gourds, grain by-products, proteins, inorganic substances, minerals, single-cell proteins, zooplankton, food waste, etc., but is not limited thereto.
[0077] Another embodiment provides a food additive or drinking water additive containing the antibiotic or the combination of antibiotics as an active ingredient. By mixing the antibiotic or the combination of antibiotics with drinking water and supplying it, the number of gram-negative bacteria in the drinking water can be reduced. The gram-negative bacteria are as described above.
[0078] Another embodiment provides a disinfectant containing the antibiotic or a combination of antibiotics as an active ingredient.Another embodiment provides a disinfection method including a step of applying the antibiotic or a combination of antibiotics to an object requiring disinfection.The disinfectant is a general term for preparations for preventing infection by pathogens, and is used as a general disinfectant for daily life, a disinfectant for food, kitchens and facilities, and a disinfectant for buildings such as poultry farms and livestock sheds, embankments, shade trees, bedding, egg beds, transport vehicles, tableware and various other growing items.
[0079] Another embodiment provides a cleaning agent containing the antibiotic or a combination of antibiotics as an active ingredient. Another embodiment provides a cleaning method comprising a step of applying the antibiotic or a combination of antibiotics to an object in need of cleaning. Since the antibiotic has an antibiotic effect against gram-negative bacteria, it can be applied for cleaning purposes such as the skin surface or various parts of the body of an individual that are exposed or may be exposed to gram-negative bacteria. The gram-negative bacteria are as described above.
[0080] Effect of the Invention The novel polypeptide, mutant of said polypeptide, or novel fusion polypeptide according to the present invention exhibits excellent outer cell membrane permeability and bactericidal activity against various Gram-negative bacteria, and is useful as an antibiotic against Gram-negative bacteria. [Brief description of the drawings]
[0081] [Figure 1] This is a cleavage map of an expression vector expressing the endolysin (LNT101) gene of bacteriophage PBPA90 that infects Pseudomonas aeruginosa. [Diagram 2] FIG. 1 shows the purification process of endolysin (LNT101) derived from bacteriophage PBPA90. [Diagram 3] 1 is a graph showing the antibiotic effect of endolysin (LNT101) derived from bacteriophage PBPA90 against Pseudomonas aeruginosa in vitro. [Figure 4] 1 is a graph showing the antibiotic effect of endolysin (LNT101) derived from bacteriophage PBPA90 against Pseudomonas aeruginosa in vivo. [Diagram 5] FIG. 1 shows a comparison of the amino acid sequences of endolysin (LNT102) (SEQ ID NO: 6) and endolysin (LNT101) (SEQ ID NO: 1) according to one embodiment. [Figure 6] 1 is a cleavage map of the expression vector pBT7-LNT102 for expression of endolysin (LNT102). [Figure 7]FIG. 1 shows the results of SDS-PAGE of reaction products obtained during the purification process of endolysin (LNT102). [Figure 8] 1 is a graph showing the bactericidal activity of endolysin (LNT102) and endolysin (LNT101) against various Gram-negative bacteria. [Figure 9] 1 is a graph showing the bactericidal activity of endolysin (LNT102) against Gram-negative bacteria as a function of concentration and treatment time. [Figure 10] 1 is a graph showing the bactericidal activity of endolysin (LNT102) against Gram-negative bacteria as a function of concentration and treatment time. [Figure 11] FIG. 1 is a schematic diagram of a fusion polypeptide (LNT103) according to one embodiment. [Figure 12] 1 is an image showing the results of SDS-PAGE of reaction products obtained during the purification process of a fusion polypeptide (LNT103) according to one embodiment. [Figure 13] 1 is a graph showing the outer membrane permeabilization activity of an endolysin (LNT101), an endolysin mutant (LNT102), and a fusion polypeptide (LNT103) against various Gram-negative bacteria. [Figure 14] 1 is a graph showing the bactericidal activity of an endolysin (LNT101), an endolysin mutant (LNT102), and a fusion polypeptide (LNT103) against a variety of Gram-negative bacteria. [Figure 15] 1 is a graph showing the bactericidal activity of fusion polypeptides LNT103 and CecA-LNT101 against various Gram-negative bacteria. [Figure 16] 1 is a graph comparing the bactericidal activity of a fusion polypeptide according to one embodiment (LNT103) and Cecropin A against Gram-negative bacteria. [Figure 17] 1 is a graph showing the gram-negative bacteria killing ability as a function of concentration and treatment time of a fusion polypeptide (LNT103) according to one embodiment. [Figure 18] 1 is a graph showing the results of a cytotoxicity and hemolysis assay of a fusion polypeptide (LNT103) according to one embodiment. [Figure 19] 1 is a graph showing the results of a cytotoxicity and hemolysis assay of a fusion polypeptide (LNT103) according to one embodiment. [Figure 20] 1 is a graph showing the survival rate of a mouse model of systemic Acinetobacter baumannii infection treated with the fusion polypeptide LNT103 compared with that of colistin.
[0082] The novel endolysin of the present invention and / or the bacteriophage expressing the same exhibit excellent growth inhibitory and bactericidal activities against Pseudomonas bacteria, such as Pseudomonas aeruginosa, and are therefore useful as antibiotics against Pseudomonas bacteria, such as Pseudomonas aeruginosa. EXAMPLES
[0083] Example 1: Preparation and antibiotic activity testing of LNT101 endolysin 1.1. Isolation of bacteriophages capable of killing Pseudomonas aeruginosa 1.1.1. Culture conditions of strains Pseudomonas aeruginosa (PR01957) was used as the host and cultured in Luria-Bertani (LB) medium at 37°C with shaking.
[0084] 1.1.2. Isolation of bacteriophages To screen for bacteriophages that infect P. aeruginosa, samples were collected from the Gwacheon Sewage Treatment Plant in Gwacheon, Gyeonggi-do, South Korea. The collected samples and P. aeruginosa were cultured with shaking at 37°C for 3 hours, then centrifuged at 500 rpm for 20 minutes to collect the supernatant. The supernatant was then filtered through a 0.45 μm filter and subjected to a double agar layer plaque assay.
[0085] Briefly, the assay consisted of mixing the host bacterium Pseudomonas aeruginosa and the bacteriophage culture at 0.1 MOI in 5 ml of top agar, pouring it onto an agar plate, and culturing it at 37°C for 24 hours to obtain plaques. By repeating the above process, a purified bacteriophage was obtained, which was named bacteriophage PBPA90.
[0086] 1.2: Genome isolation and analysis of bacteriophage PBPA90 The genome of the bacteriophage PBPA90 obtained in Example 1.1 was sequenced. Pseudomonas aeruginosa was cultured in 200 ml of LB medium at OD 600 After culturing until the temperature reached 0.5, 10 filtered bacteriophage were added. 9 The cells were infected with pfu / ml or 0.1 MOI and lysed. Sodium chloride was then added to the cells to a final concentration of 1M, and the cells were left at 4°C for 1 hour. After centrifugation at 11,000×g for 10 minutes, PEG (polyethylene glycol 8000) was added to the precipitate to a concentration of 10% (w / v) and the precipitate was left at 4°C for 1 hour. After centrifugation at 11,000×g for 10 minutes, the supernatant was removed and the precipitate was suspended in SM buffer [100 mM NaCl, 10 mM MgSO4 (heptahydrate), 50 mM Tris-HCl, pH 7.5]. Chloroform was added in a 1:1 ratio and vortexed, followed by centrifugation at 3,000×g for 15 minutes to obtain the supernatant.
[0087] Three ml of 40% (w / v) glycerol was added to a polycarbonate test tube, followed by 4 ml of 5% (w / v) glycerol without mixing. The prepared supernatant was added thereto and centrifuged at 11,000 x g at 4°C for 1 hour. The supernatant was then removed, and the precipitate was resuspended in SM buffer to obtain bacteriophage genomic DNA. Bacteriophage genomic DNA was isolated using a phage DNA isolation kit (Norgen biotek corp.) according to the manufacturer's instructions. The genome sample isolated in this way was used to analyze the genome sequence (LAS, Illumina MiSeq platform).
[0088] The final analyzed bacteriophage PBPA90 genome had a total nucleic acid sequence length of 304,052 bp and a GC content of 44%. The full-length nucleic acid sequence of the bacteriophage PBPA90 genome is shown in SEQ ID NO: 5. Based on the genome nucleic acid sequence information, the similarity with known bacteriophage genome sequences was examined using BLAST on the Web. As a result of the BLAST search, it was confirmed that the genome sequence of bacteriophage PBPA90 has low sequence similarity with Pseudomonas bacteriophage KTN4 (GenBank accession No.: KU521356.1) (query coverage: 4%, identity: 97.34%). Based on these facts, it was confirmed that bacteriophage PBPA90 is a new bacteriophage that has not been previously known.
[0089] 1.3: Cloning and purification of LNT101 endolysin An ORF search of the genome sequence (sequence number 5) of bacteriophage PBPA90 analyzed above predicted that the 780 bp (sequence number 2) ORF at positions 180, 029-180, and 806 was an endolysin gene, and the endolysin derived from bacteriophage PBPA90 and the gene encoding it were named LNT101 endolysin and LNT101 gene, respectively. Using primers (F: 5'-aaggatccatgggtactgtactcaaacgtggc-3' (SEQ ID NO: 3), R: 5'-aactcgagtgcccgatgtttcgaaactttatcttc-3' (SEQ ID NO: 4), PCR (polymerase chain reaction) was performed on the genome of bacteriophage PBPA90 to obtain the LNT101 gene (a 780 bp long nucleic acid sequence from positions 180,029 to 180,806 of SEQ ID NO: 5). The amino acid sequence of the LNT101 endolysin encoded by the LNT101 gene was determined to be SEQ ID NO: 1 (259a The PCR was carried out under the following conditions: step 1: 94°C, 5 min; step 2: 94°C, 30 sec; step 3: 52°C, 45 sec; step 4: 72°C, 1 min; step 5: steps 2 to 4 repeated 30 times; step 6: 72°C, 10 min. The PCR product obtained above was cloned into the BamHI / XhoI site of pET-21a vector (Novagen) having an N-terminal 6×His tag to prepare an expression vector (pET-LNT101 plasmid) for expressing LNT101 endolysin. The expression vector pET-LNT101 prepared above is shown in FIG. 1.
[0090] The pET-LNT101 plasmid prepared above was transformed into E. coli BL21-pLysS strain (Novagen), and the OD 600The cells were cultured until the pH reached 0.5. After that, 1 mM IPTG (isopropyl β-d-1-thiogalactopyranoside) was added, and the cells were cultured at 37°C for 4 hours with shaking. After collecting the cells, they were resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole), and 1 mM PMSF and 1 mg / ml lysozyme were added, and the cells were left to stand on ice for 30 minutes. The cells were lysed by sonication, and centrifuged at 13,000 rpm for 40 minutes to obtain the supernatant. The supernatant was passed through a column packed with Ni-NTA agarose resin (Qiagen). Then, the mixture was washed with a washing buffer (50 mM NaH2PO4, 300 mM NaCl, 30 mM imidazole) and then eluted with an elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole) to purify the LNT101 protein (containing a 6xHis tag).
[0091] The purity of the LNT101 protein was confirmed by 15% SDS-PAGE, and the concentration of the LNT101 protein was measured by the Bradford test. The results of SDS-PAGE of each reaction product obtained during the purification process are shown in Figure 2. The molecular weight of the purified LNT101 protein confirmed by SDS-PAGE was about 28 kDa. The amino acid sequence of the LNT101 protein is shown in SEQ ID NO:1.
[0092] 1.4. Investigation of the target bacterial spectrum of bacteriophage PBPA90 and its derived endolysin LNT101 In this example, in order to investigate the target bacterial spectrum of the bacteriophage PBPA90 selected in Examples 1.1 and 1.2 and the endolysin LNT101 isolated and purified in Example 1.3, Pseudomonas aeruginosa ATCC13388, ATCC9027, ATCC10145, ATCC15692, ATCC15522, ATCC25619, ATCC27853, CCARM2134, CCARM2200, CCARM2029, CCARM2144, CCARM220 ... The antibacterial activity against Gram-negative bacteria including M2298, CCARM2326, PR01957, Escherichia coli ATCC8739, Enterobacter cloacae CCARM0252, Klebsiella pneumoniae KCTC2261, Klebsiella aerogenes CCARM16006, Campylobacter jejuni KCTC5327, Cronobacter sakazakii KCTC2949, Salmonella typhimurium ATCC14028, and Salmonella enteritidis ATCC13076 was tested.
[0093] The target bacterial spectrum of bacteriophage PBPA90 and endolysin LNT101 was confirmed by spot testing. The spot test consisted of 1 × 10 sterilized bacteria in 4 ml of top agar (1% tryptone, 0.5% yeast extract, 0.5% NaCl, 0.7% agar). 11 CFU / 200 μl was added and poured onto an LB plate. After the top agar solidified, 10 μl (1 × 10 8 PFU / ml) or LNT101 (10 μl / ml) was spotted onto the plate and incubated at 37° C. for 18 hours.
[0094] The occurrence of a halo zone formed as a result of the incubation was confirmed, and the results are shown in Table 1 below.
[0095] [Table 1]
[0096] As shown in Table 1 above, endolysin LNT101 formed growth inhibition zones in all tested Gram-negative bacteria, namely, Pseudomonas aeruginosa, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, Campylobacter, Cronobacter, and Salmonella strains. This result indicates that endolysin LNT101 has the ability to degrade peptidoglycan of various Gram-negative bacteria as mentioned above, and has a broad spectrum of target bacteria.
[0097] 1.5. Investigation of the bactericidal activity of endolysin LNT101 against Pseudomonas aeruginosa In this example, the bactericidal activity of endolysin LNT101 was tested against Pseudomonas aeruginosa (ATCC 13388), for which bacteriophage PBPA90 and endolysin LNT101 were confirmed to have antibacterial activity in Example 1.4.
[0098] In vitro testing For this purpose, endolysin LNT101 at concentrations of 0.1, 0.5, and 1.0 μM and Pseudomonas aeruginosa (ATCC 13388) 1 × 10 6 CFU were added to a final volume of 200 μl of reaction buffer (20 mM Tris-Cl, pH 7.5) and incubated at 37°C for 1 h. After 30 min, 1 h, and 2 h, the colony counts of P. aeruginosa were counted and the results are shown in Figure 3. As shown in Figure 3, endolysin LNT101 was confirmed to have bactericidal activity against P. aeruginosa at all treatment doses and times tested, and such bactericidal activity against P. aeruginosa was shown to be treatment time- and dose-dependent.
[0099] Furthermore, it was confirmed by CFU reduction tests that the LNT101 endolysin has antibacterial activity against a variety of Gram-negative bacteria, and the results are shown in Table 2 below.
[0100] [Table 2]
[0101] As shown in Table 2 above, it was confirmed that the drug had a dose-dependent bacterial killing effect on all tested Gram-negative bacteria, including eight species of Pseudomonas aeruginosa, three species of Acinetobacter baumannii, one species of Enterobacter cloacae, and one species of Klebsiella aerogenes, including drug-resistant bacteria.
[0102] In vivo testing The ability of endolysin LNT101 to kill P. aeruginosa was also confirmed in vivo. Galleria mellonella was used as an animal model for the in vivo efficacy evaluation. The Galleria mellonella model was divided into a healthy group (non-infected group), a P. aeruginosa-infected group (non-drug-administered group), two LNT101-administered groups in which LNT101 was administered to the infection model, a colistin-administered group in which colistin was administered to the P. aeruginosa-infected model, and a combination-administered group in which LNT101 and colistin were administered in combination to the P. aeruginosa-infected model. Ten Galleria mellonella were used for each group.
[0103] The P. aeruginosa infection model was prepared by infecting P. aeruginosa PAO1 with LD80 concentration of 50 CFU / larvae, and administering LNT101 at 0.6μg / larvae (3mg / Kg) or 6μg / larvae (30mg / Kg). Colistin was administered at 0.5μg / larvae (2.5mg / Kg), and in the case of combined administration, colistin was administered at 0.5μg / larvae (2.5mg / Kg) and LNT101 at 6μg / larvae (30mg / Kg). The survival rate of Galleria mellonella after 72 hours of observation is shown in Figure 4. As shown in Figure 4, 100% of the infected group died, but the survival rate was confirmed to increase in the LNT101 and colistin groups. In particular, the survival rate of 30% was confirmed in the LNT101 6μg / larvae (30mg / Kg) group.
[0104] 1.6. Synergistic effect of endolysin LTN101 and polymyxin antibiotics on killing Pseudomonas aeruginosa We confirmed the synergistic effect of combined treatment of polymyxin antibiotics, which act on bacterial cell membranes, and endolysin LNT101. Specifically, polymyxin B (32μg / ml-0.03μg / ml) and colistin (128μg / ml-0.1μg / ml) were diluted in half per well in a microplate, and then a group was created in which LNT101 endolysin was combined with 1μM and a group was created in which the same amount of PBS was treated. All wells were then cultured with 1×10 P. aeruginosa bacteria. 5 CFU / ml was treated with a total of 100 μl. Then, the wells were cultured for 18 hours at 37°C. MIC (minimum inhibitory concentration) means the minimum concentration of polymyxin antibiotics in which bacteria do not grow, and the MIC test was performed by broth microdilution method.
[0105] The changes in MIC of polymyxin antibiotics (polymyxin B, colistin) upon combined treatment with various concentrations of polymyxin antibiotics and LNT101 endolysin were confirmed and are shown in Table 3 below.
[0106] [Table 3]
[0107] As shown in Table 3 above, it was confirmed that the MICs of the polymyxin antibiotics polymyxin B and colistin were reduced by 50% when LNT101 endolysin was used in combination.
[0108] Example 2. Generation of LNT102 endolysin and antibiotic activity testing 2.1. Discovery of novel polypeptides with endolysin activity Endolysin LNT101 (SEQ ID NO: 1) isolated and purified in Example 1.3 is composed of a PG_binding_1 domain (10 to 65 amino acid residues) and a transglycosylase SLT domain (95 to 179 amino acid residues).
[0109] The amino acid sequence of the PG_binding_1 domain of endolysin LNT101 was compared by BLASTp analysis with the amino acid sequences of the following genes with similar amino acid sequences, and 11 amino acids of the LNT101 endolysin and other amino acid sites were replaced with the dominant amino acid sequences of the compared proteins: glycosylhydrolase family 25 of Thermoanaerobacter phage THSA-485A (accession no. YP_006546280.1), peptidoglycan binding protein of Serratia phage phiMAM1 (accession no. YP_007349105.1), peptidoglycan binding protein of Serratia phage 2050H1 (accession no. ASZ78903.1), putative peptidoglycan binding protein of Serratia phage vB_SmaA_3M (accession no. ASZ78903.1), and putative peptidoglycan binding protein of Serratia phage vB_SmaA_3M (accession no. ASZ78903.1). no. AYP28388.1), the putative peptidoglycan-binding protein of Enwinia phage vB_EamM-Bue1 (accession no. AVO22912.1), the putative peptidoglycan-binding protein of Pseudomonas phage Noxifer (accession no. YP_009609055.1), the endolysin of Salmonella phage Mutine (accession no. AUG88272.1) and the peptidoglycan-binding protein of Salmonella phage bering (accession no. QIQ61961.1).
[0110] The amino acid sequence of the LNT101 endolysin transglycosylase SLT domain was compared by BLASTp analysis with the amino acid sequences of the following genes with similar amino acid sequences, and four amino acids of the LNT101 endolysin and other amino acid sites were replaced with the dominant amino acid sequences of the compared proteins: tail fiber protein of Pseudomonas phage Noxifer (accession no. YP_009609112.1), hypothetical protein SL2_199 of Pseudomonas phage SL2 (accession no. YP_009619739.1), putative endolysin of Pseudomonas phage KTN4 (accession no. ANM44938.1), PHIKZ144 of Pseudomonas phage phiKZ (accession no. NP_803710.1), tail fiber protein of Pseudomonas phage Psa21 (accession no. NP_803710.1), and the tail fiber protein of Pseudomonas phage Psa21 (accession no. NP_803710.1). no. QBJ02724.1) and the hypothetical protein of Pseudomonas phage vB_PaeM_PS119XW (accession no. QEM41943.1).
[0111] In the LNT101 gene sequence, 15 substituted amino acid sequence portions were changed in consideration of codon usage (SEQ ID NO: 7), and this was named LNT102 (SEQ ID NO: 6). A comparison of the sequences of LNT101 and LNT102 is shown in FIG. 5. LNT102 was gene synthesized and cloned into a C-terminal 6× histidine tagged pBT7-C-His vector (Bionia). The LNT102 expression vector pBT7-LNT102 thus prepared is shown diagrammatically in FIG. 6.
[0112] The sequences of LNT102 and LNT101 are summarized in Table 4 below.
[0113] [Table 4]
[0114] Purification of LNT102 endolysin The prepared pBT7-LNT102 plasmid was transformed into E. coli BL21-Star (DE3) strain (Invitrogen), and then grown at OD 400 in LB liquid medium (1% tryptone, 0.5% (w / v) yeast extract, 0.5% (w / v) NaCl). 600 The cells were cultured until the pH reached 0.5. After that, 1 mM IPTG (isopropyl β-d-1-thiogalactopyranoside) was added, and the cells were cultured at 37°C for 4 hours with shaking. After collecting the cells, they were resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole), and 1 mM PMSF and 1 mg / ml lysozyme were added, and the cells were left to stand on ice for 30 minutes. The cells were lysed by sonication, and centrifuged at 13,000 rpm for 40 minutes to obtain the supernatant. The supernatant was passed through a column packed with Ni-NTA agarose resin (Qiagen). Then, the mixture was washed with a washing buffer (50 mM NaH2PO4, 300 mM NaCl, 30 mM imidazole) and then eluted with an elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole) to purify the LNT102 protein (containing a 6xHis tag).
[0115] The purity of the LNT102 protein was confirmed by 15% SDS-PAGE, and the concentration of the LNT102 protein was measured by the Bradford test. The results of SDS-PAGE of each reaction product obtained in the purification process are shown in Figure 7. The molecular weight of the purified LNT102 protein confirmed by SDS-PAGE was about 28 kDa.
[0116] 2.3. Investigation of the bactericidal activity of endolysin LNT102 against Gram-negative bacteria In this example, the bactericidal activity and target bacterial spectrum of endolysin LNT102 purified in Example 2.2 were confirmed against various Gram-negative bacteria.
[0117] In vitro testing To this end, endolysins LNT101 and LNT102 at 2 μM concentration and 1 × 10 of Pseudomonas aeruginosa (PAO1; ATCC 15692), Acinetobacter baumannii (ATCC17978), Escherichia coli (ATCC 8739), Klebsiella pneumoniae (ATCC 13883), Enterobacter aerogenes (CCARM 16006), and Salmonella enteritidis (ATCC 13076), respectively, were incubated at 37 °C for 1 h at 4 °C. 6 CFUs were added to a reaction buffer (20 mM Tris-Cl, pH 7.5) to a final volume of 200 μl, and allowed to stand at 37° C. for 2 hours. After 2 hours, the colony counts of each Gram-negative bacterium were counted, and the results are shown in FIG. 8 (in FIG. 8, PA90 represents endolysin LNT101, and mtPA90 represents endolysin LNT102). As shown in FIG. 8, both endolysins LNT101 and LNT102 were confirmed to have superior bactericidal activity against all Gram-negative bacteria tested, compared to the control group, and in particular, LNT102 showed superior bactericidal activity against Gram-negative bacteria compared to LNT101 at the same dose.
[0118] Endolysin LNT102 at concentrations of 0.1, 0.5, and 2.5 μM and Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherichia coli were incubated at 1 × 10 6 The CFUs were added to a final volume of 200 μl of reaction buffer (20 mM Tris-Cl, pH 7.5) and incubated at 37° C. for 2 hours. After 30 minutes, 1 hour, and 2 hours, the colony counts of each Gram-negative bacterium were counted, and the results are shown in Figures 9 and 10. As shown in Figures 9 and 10, it was confirmed that endolysin LNT102 had bactericidal activity against Gram-negative bacteria at all treatment doses and times tested, and such bactericidal activity against Gram-negative bacteria was shown to be dependent on the treatment time and dose.
[0119] 2.4. Synergistic effect of endolysin LTN102 and antibiotics on the killing of Gram-negative bacteria A synergistic effect was confirmed by combined treatment of polymyxin antibiotics, which act on bacterial cell membranes, and endolysin LNT102, purified in Example 2.2. Specifically, row A of a 96-well microplate was treated with 4 μg / ml polymyxin B, and then serially diluted in half in rows B to G. Row H was not treated with polymyxin. Row A of a 96-well microplate was treated with 8 μg / ml colistin, and then serially diluted in half in rows B to G. Row H was not treated with polymyxin. Then, a combined treatment group was further treated with 1 μM LNT102 endolysin, and a group treated with the same amount of PBS was created. All wells were filled with 1 × 10 6 each of Pseudomonas aeruginosa and Escherichia coli. 5 CFU / ml, total volume of 100μl. Then, it was cultured at 37℃ for 18 hours. MIC (minimum inhibitory concentration) means the minimum concentration value of polymyxin antibiotic in the well where bacteria do not grow. MIC test was performed by broth microdilution method according to the standard test method of CLSI (Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 11th ed. Document M07. Wayne, PA: CLSI; 2018).
[0120] The changes in MIC of polymyxin antibiotics (polymyxin B, colistin) following combined treatment with various concentrations of polymyxin antibiotics and LNT102 endolysin were measured and are shown in Table 5 below.
[0121] [Table 5]
[0122] As shown in Table 5 above, it was confirmed that the MICs of polymyxin antibiotics, polymyxin B and colistin, were reduced by up to 1 / 16 when LNT102 endolysin was used in combination. These results indicate that a significantly increased antibiotic effect can be obtained when existing antibiotics, for example, polymyxin antibiotics, are used in combination with LNT102 endolysin.
[0123] Example 3: Production of fusion polypeptides 3.1. Preparation of Polypeptides (LNT101 and LNT102 Endolysins) Endolysin LNT101 (SEQ ID NO: 1) is composed of a PG_binding_1 domain (10 to 65 amino acid residues) and a transglycosylase SLT domain (95 to 179 amino acid residues). In addition to the 15 amino acid mutations of endolysin LNT101 (SEQ ID NO: 1), an endolysin LNT101 mutant of SEQ ID NO: 6 (hereinafter, named endolysin LNT102) was prepared.
[0124] The coding gene for endolysin LNT102 (SEQ ID NO: 7) was inserted into pBT7 plasmid to prepare pBT7-LNT102 plasmid for expressing endolysin LNT102. The prepared pBT7-LNT102 plasmid was transformed into E. coli BL21-Star (DE3) strain (Invitrogen), and then grown at OD 3000 in LB liquid medium (1% tryptone, 0.5% (w / v) yeast extract, 0.5% (w / v) NaCl). 600The cells were cultured until the pH reached 0.5. After that, 1 mM IPTG (isopropyl β-d-1-thiogalactopyranoside) was added, and the cells were cultured at 37°C for 4 hours with shaking. After recovery, the cells were resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole), and 1 mM PMSF and 1 mg / ml lysozyme were added, followed by incubation on ice for 30 minutes. The cells were lysed by sonication, and centrifuged at 13,000 rpm for 40 minutes to obtain the supernatant. The supernatant was passed through a column packed with Ni-NTA agarose resin (Qiagen). Then, the mixture was washed with a washing buffer (50 mM NaH2PO4, 300 mM NaCl, 30 mM imidazole) and then eluted with an elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole) to purify the LNT102 protein (containing a 6xHis tag).
[0125] The purity of the LNT102 protein was confirmed by 15% SDS-PAGE, and the concentration of the LNT102 protein was measured by the Bradford test. As a result of confirming each reaction product obtained in the purification process by SDS-PAGE, the molecular weight of the purified LNT102 protein was about 31 kDa.
[0126] 3.2. Preparation of Fusion Polypeptides A fusion polypeptide was prepared by fusing cecropin A to the prepared LNT102 protein. Specifically, a polynucleotide (SEQ ID NO: 11) encoding a fusion polypeptide (named LNT103) (SEQ ID NO: 10) including [cecropin A (SEQ ID NO: 8)]-[linker (GSGSGS) (SEQ ID NO: 12)]-[endolysin (named LNT102) (SEQ ID NO: 6)] in the order from the N-terminus was inserted into a pET 21a (Novagen) plasmid to prepare a plasmid pET-LNT103 for expressing LNT103. The prepared pET-LNT103 plasmid was transformed into E. coli BL21-Star (DE3) strain (Invitrogen), and then incubated at OD 1000 for 1 h in LB liquid medium (1% (w / v) tryptone, 0.5% (w / v) yeast extract, 0.5% (w / v) NaCl). 600 Cultured until the pH was 0.5.
[0127] After that, 1 mM IPTG (isopropyl β-D-1-thiogalactopyranoside e) was added and the cells were cultured at 25°C for 6 hours with shaking. After recovery of the cells, they were resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole), and 1 mM PMSF (phenylmethylsulfonyl fluoride) and 1 mg / ml lysozyme were added and left on ice for 30 minutes. The cells were lysed by ultrasonic treatment and centrifuged at 13,000 rpm for 40 minutes to obtain the supernatant. The supernatant obtained above was passed through a column packed with Ni-NTA agarose resin (Qiagen). After washing with washing buffer (50 mM NaH2PO4, 300 mM NaCl, 30 mM imidazole), it was eluted with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole). Purification / confirmation was performed by 15% SDS-PAGE and concentration was determined by Bradford test.
[0128] The results of the SDS-PAGE obtained above are shown in Figure 12. As can be seen from Figure 12, the molecular weight of the purified fusion polypeptide LNT103 (SEQ ID NO: 10) was confirmed to be 34 KDa.
[0129] In addition, a fusion polypeptide (CecA-LNT101; SEQ ID NO: 13) was prepared by fusing cecropin A to endolysin LNT101 (SEQ ID NO: 1) in the same manner as described above. The prepared CecA-LNT101 was subjected to SDS-PAGE by the method described above, and the molecular weight of CecA-LNT101 was confirmed to be 34 kDa.
[0130] Meanwhile, for ease of testing, the purified fusion polypeptides LNT103 (SEQ ID NO: 10) and CecA-LNT101 (SEQ ID NO: 13) were prepared by substituting the first amino acid M with MAS (Met-Ala-Ser) and adding a His tag as an extra sequence to the C-terminus (SEQ ID NO: 15 or SEQ ID NO: 16). In the tests described below, SEQ ID NO: 15 was used as the fusion polypeptide LNT103, and SEQ ID NO: 16 was used as the CecA-LNT101.
[0131] The amino acid sequences and nucleic acid sequences of the polypeptides described in this Example and the genes encoding them are summarized in Table 6 below:
[0132] [Table 6-1]
[0133] [Table 6-2]
[0134] 3.3. Evaluation of outer membrane permeabilization activity of the fusion polypeptide LNT103 To evaluate the outer membrane permeabilization activity of the fusion polypeptide prepared in Example 3.2 in Gram-negative bacteria, an NPN uptake assay was performed using Pseudomonas aeruginosa and Acinetobacter baumannii as representative Gram-negative bacteria.
[0135] Pseudomonas aeruginosa (PAO1; ATCC 15692) or Acinetobacter baumannii (ATCC 19606) were cultured at OD 600=0.3, and then centrifuged at 1,000g for 10 minutes, and resuspended in about 1 / 2 volume of 5 mM HEPES (hydroxyethylpiperazineethanesulfonic acid) (pH 7.2). 50 μl of 40 μM NPN (1-N-phenylnaphthylamine) solution (40 μM NPN in 5 mM HEPES, pH 7.2), 50 μl of test substance (LNT101, LNT102 or LNT103), and 100 μl of strain suspension (total 200 μl) were placed in a microplate and reacted at 37 ° C for 1 hour. Fluorescence was then measured using a microplate reader (Infinite M200 Pro, TECAN) at an excitation wavelength of 350 nm and an emission wavelength (enussion) of 420 nm. Cecropin A (cecropin A; SEQ ID NO: 8), EDTA, or polymyxin B were used as positive controls, and 10 μM NPN solution was used as a negative control. All experiments were performed in triplicate.
[0136] The results obtained above are shown in FIG. 13. To compare the outer membrane permeability activities of LNT101, LNT102, and LNT103 against Gram-negative bacteria (Pseudomonas aeruginosa (PAO1; ATCC 15692) and Acinetobacter baumannii (ATCC 19606), the same concentration of 2 μM was used, and cecropin A and polymyxin B were used at 2 μM and EDTA was used at 1 mM. The results obtained above are shown in A and B of FIG. 13 as fold change over negative control. As shown in A and B of FIG. 13, the fusion polypeptide LNT103 was confirmed to have a higher outer membrane permeability activity against Gram-negative bacteria than the polypeptides LNT101 and LNT102 at the same concentration, and was confirmed to have a higher activity than the positive controls, cecropin A, EDTA, and polymyxin B.
[0137] On the other hand, to confirm the difference in the cell outer membrane permeability activity against Gram-negative bacteria (Pseudomonas aeruginosa (PAO1; ATCC 15692) and Acinetobacter baumannii (ATCC 19606) depending on the concentration of LNT103, LNT103 was treated at 0.29 μM, 0.88 μM, or (2.65 μM), cecropin A and polymyxin B were treated at 2 μM, and EDTA was treated at 1 mM. The results obtained above are shown in Fig. 13C and D as fold change over negative control. As shown in Fig. 13C and D, LNT103 had superior cell outer membrane permeability activity against Gram-negative bacteria compared to LNT101, LNT102, cecropin A, and polymyxin B, and it was confirmed that the cell outer membrane permeability activity against Gram-negative bacteria increased in a concentration-dependent manner.
[0138] 3.4. Investigation of the bactericidal activity of the fusion polypeptide LNT103 against Gram-negative bacteria In order to confirm the bactericidal activity of the fusion polypeptide LNT103 prepared in Example 3.2 against Gram-negative bacteria, a CFU reduction test was performed against various Gram-negative bacteria. To perform the CFU reduction test, LNT101, LNT102, and LNT103 prepared in Example 3 were each diluted at 2 μM, and Pseudomonas aeruginosa (PAO1; ATCC 15692), Acinetobacter baumannii (ATCC 19606, ATCC 17978), Escherichia coli (ATCC 8739), Klebsiella pneumoniae (ATCC 2208), and Enterobacter aerogenes (CCARM 16006) were each diluted at 1 × 10 6 CFU were added to a reaction buffer (20 mM Tris-Cl, pH 7.5) to a final volume of 200 μl, and left to stand at 37°C for 2 hours. The colony counts of each Gram-negative bacterium were then counted to comparatively evaluate the antibiotic effect of each polypeptide. A PBS-treated group (treated with the same volume of PBS as the fusion polypeptide) was used as a control group.
[0139] The results obtained above are shown in Figure 14. As shown in Figure 4, it was confirmed that the fusion polypeptide LNT103 exhibited a CFU reduction effect of 1.5 to 5.5 log CFU / ml compared to LNT101 and LNT102. In particular, the CFU coefficient results (log CFU / ml) of the fusion polypeptide LNT103 against Acinetobacter baumannii (ATCC 19606, ATCC 17978), Escherichia coli (ATCC 8739), and Klebsiella pneumoniae (ATCC 2208) were 0, killing all bacteria treated.
[0140] In addition, a similar test was performed using the fusion polypeptides LNT103 and CecA-LNT101 at a concentration of 2 μM, and the results are shown in FIG. 15. For comparison, a similar test was performed on the groups treated with LNT102 or PBS. As shown in FIG. 15, the groups treated with the fusion polypeptides LNT103 and CecA-LNT101 all had superior antibiotic activity to the groups treated with LNT102 or PBS. In particular, when LNT103 and CecA-LNT101 were treated at a concentration of 2 μM, the counting results (log CFU / ml) for all the tested bacteria were expressed as 0, confirming that all the bacteria were killed.
[0141] Meanwhile, to compare the antibacterial activity of cecropin A fused to a protein other than endolysin (LNT102 or LNT101), the gram-negative bactericidal activity of the fusion polypeptide LNT103 and cecropin A-EGFP fusion protein (a protein in which LNT103 is replaced with LNT102 and EGFP (GenBank Accession No. AAB02572.1) which does not have endolysin activity is fused) was evaluated. For this purpose, the proteins were treated at 0.2 μM or 2 μM, respectively, and a CFU reduction test was performed. The results obtained above are shown in FIG. 16. As shown in FIG. 16, it was confirmed that the cecropin A-EGFP fusion protein has no antibacterial activity, whereas the fusion polypeptide LNT103 has excellent antibacterial activity. In particular, when LNT103 was treated at 2 μM, the result of counting the CFUs against all tested gram-negative bacteria (log CFU / ml) confirmed that all bacteria treated with 0 were killed.
[0142] We also tested the bactericidal activity of the fusion polypeptide LNT103 against Gram-negative bacteria as a function of the concentration and / or treatment time. Specifically, we tested the bactericidal activity of the fusion polypeptide LNT103 at 0.1, 0.3, 0.9, or 2.7 μM concentrations and 1 × 10 of Pseudomonas aeruginosa (PAO1; ATCC 15692) or Acinetobacter baumannii (ATCC 19606). 6 CFU was added to a reaction buffer (20 mM Tris-Cl, pH 7.5) to a final volume of 200 μl, and after standing at 37° C. for 2 hours, the number of colonies was counted. The results are shown in FIG. 17A.
[0143] In addition, the fusion polypeptide LNT103 at a concentration of 2 μM and Pseudomonas aeruginosa (PAO1; ATCC 15692) at 1 × 10 6 CFU was added to a reaction buffer (20 mM Tris-Cl, pH 7.5) to a final volume of 200 μl, and the number of colonies was counted after 0, 20, 40 and 60 minutes at 37° C. The results are shown in FIG. 17B.
[0144] In addition, the fusion polypeptide LNT103 at a concentration of 1 μM and Acinetobacter baumannii (ATCC 19606) at 1 × 10 6 CFU was added to a reaction buffer (20 mM Tris-Cl, pH 7.5) to a final volume of 200 μl, and the number of colonies was counted after 0, 1, 3, 5 and 10 minutes at 37° C. The results are shown in FIG. 17C.
[0145] As shown in Figures 17A, B, and C, the fusion polypeptide LNT103 was confirmed to have bactericidal activity against Gram-negative bacteria in a concentration- and time-dependent manner (the areas where no bar graphs are shown in Figures 17A, B, and C have a log CFU / ml value of 0, which means that all treated bacteria were killed).
[0146] In addition, the MIC (minimum inhibitory concentration) and MBC (minimum bactericidal concentration) of the fusion polypeptide LNT103 were measured. The MIC and MBC were measured by the microdilution method according to the standard test method of the Clinical and Laboratory Standards Institute (CLSI), but the test method was performed using CAA medium (Cas amino acids 5 g / L, K2HPO4 5.2 mM, MgSO4 1 mM) instead of MH liquid medium (casein acid hydrolysate 17.5 g / L, bovine extract 3.0 g / L, starch 1.5 g / L, pH 7.3) (Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 11 th ed. Document M07. Wayne, PA: CLSI; 2018). Specifically, rows of a 96-well microplate were treated with LNT103 at a concentration of 64 μg / ml, and rows B-G were treated with LNT103 at concentrations serially diluted by 1 / 2. Row H was not treated with LNT103. All wells were then inoculated with 5 × 105 CFU / ml, total volume of 100μl. Then, it was cultured at 37℃ for 18 hours. MIC was determined as the lowest concentration at which bacteria did not grow, and MBC was determined as the lowest concentration at which colonies were not observed by checking the colony count in each well. The results obtained above are shown in Tables 7 to 9 below.
[0147] [Table 7]
[0148] [Table 8]
[0149] [Table 9]
[0150] 3.5. Synergistic effect of the fusion polypeptide LNT103 in combination with polymyxin antibiotics on the killing of Gram-negative bacteria We confirmed the synergistic bactericidal effect of the combined treatment of polymyxin antibiotics, which act on bacterial cell membranes, and the fusion polypeptide LNT103 on gram-negative bacteria. Specifically, column 1 of a 96-well microplate was treated with colistin (polymyxin E) at 16 μl / ml, and columns 2 to 11 were treated with concentrations serially diluted by 1 / 2. Column A was treated with 16 μg / ml LNT103, and columns B to G were treated with concentrations serially diluted by 1 / 2. Then, all wells were inoculated with Acinetobacter baumannii (ATCC 19606) at 5 × 10 5 CFU / ml, total volume of 100 μl was treated. After that, the cells were cultured at 37°C for 18 hours, and the fractional inhibitory concentration (FIC) index value was calculated using the following formula.
[0151] FIC index = FIC A +FIC B =(CA / MIC A )+(CB / MIC B ) (C A and CB is the respective concentration of the combined treated substances (polymyxin E and LNT103), and MIC A and MIC B is the MIC of a single drug. FIC value: synergy effect<0.5;antagonism>4;additive 0.5-4)
[0152] As a result of the test, the FIC index value was expressed as 0.375, confirming the synergistic effect between the two substances.
[0153] 3.6. In vitro toxicity evaluation of the fusion polypeptide LNT103 The in vitro toxicity of the fusion polypeptide LNT103 was evaluated in a cytotoxicity test using the Huh-7 cell line (WST test) and a hemolysis test using sheep blood (MB cells).
[0154] The cytotoxicity test procedure is as follows: Huh-7 cell culture medium was prepared and cultured in a 96-well plate at 1 × 10 cells per well. 9The cells were dispensed in an amount of cells / well and cultured in a CO2 incubator for 24 hours. Then, the cells were treated with PBS as a negative control, 1% (w / v) triton X-100 as a positive control, and fusion polypeptide LNT103 at a concentration of 0.25, 0.5, or 1 mg / ml as an experimental group, and then left to stand in a CO2 incubator for 24 and 48 hours. Then, cell viability was measured using a D-Plus™ CCK cell viability assay kit (Dongin LS), and the results are shown in Figure 18. As shown in Figure 18, when treated with fusion polypeptide LNT103 at a concentration of 0.25 mg / ml, 0.5 mg / ml, or 1 mg / ml for 24 hours, the cell viability was 93%, 90%, and 78%, respectively, compared to the negative control (PBS), and when treated for 48 hours, the cell viability was 108%, 105%, and 86%, respectively, compared to the negative control. In other words, the fusion polypeptide LNT103 treatment showed a cell viability of about 80% or more compared to the control group (PBS), confirming that the cytotoxicity was relatively low. As a result, the IC50 of LNT103 was confirmed to be >1 mg / ml.
[0155] The hemolysis test proceeded as follows. 3 ml of sheep blood was mixed with 14 ml of PBS (pH 7.2), and centrifuged at 1000 g for 5 minutes at 4°C to remove the supernatant. The removed volume was then filled with PBS again, and the above washing process was carried out a total of four times. The hemoglobin dissolved by washing was removed, and after the final centrifugation, 400 μl of the settled RBCs (red blood cells) were dissolved in 9.6 ml of PBS to prepare a 4% (v / v) blood solution. 50 μl of sample and 50 μl of 4% (v / v) blood solution were mixed in a 96-well microplate and reacted at 37°C for 1 hour. The experimental group was treated with fusion polypeptide LNT103 at a two-fold dilution range from 128 μg / ml to 2 μg / ml (PBS, pH 7.2), the positive control group was treated with 0.1% (w / v) Triton X-100, and the negative control group was treated with PBS. After 1 hour of reaction, the microplate was centrifuged at 1000g for 5 minutes at 4°C, and 50 μl of the supernatant was transferred to a new microplate and the absorbance was measured at 570 nm (Infinite M200 Pro, TECAN). The results obtained above are shown in Figure 19. As shown in Figure 19, it was confirmed that the fusion polypeptide LNT103 did not show hemolytic activity at all concentrations tested. As a result, it was confirmed that the MHC (minimum hemolytic concentration) of LNT103 was >128 μg / ml.
[0156] 3.7. In vivo efficacy evaluation of fusion polypeptide LNT103 To evaluate the in vivo efficacy of the fusion polypeptide LNT103, survival was confirmed in a mouse model of systemic infection with Acinetobacter baumannii ATCC 19606.
[0157] The animal experiment proceeded as follows. Four-week-old male ICR mice were purchased and used after a one-week acclimation period when they were 5-6 weeks old and weighed 20-21 g. Acinetobacter baumannii was mixed with 10% mucin at a ratio of 1:1 and 2 × 10 8A bacterial solution of CFU / ml (5% mucin) was inoculated intraperitoneally into mice. One hour and four hours after infection, 20mpk LNT103, 100mpk LNT103, and 20mpk colistin as a comparison group were administered by subcutaneous injection. The survival rate was then confirmed for 96 hours, and the results are shown in FIG. 20. As shown in FIG. 20, the group administered with LNT103 in the systemic infection mouse model showed a higher survival rate than the non-administered group (control) and the comparison group (colistin-administered group), and since LNT103 shows a high survival rate in a concentration-dependent manner, it was confirmed that it is effective in the mouse model.
[0158] From the above description, a person skilled in the art to which the present invention belongs can understand that the present invention can be implemented in other embodiments without changing its technical idea or essential features. In this regard, it should be understood that the above-described embodiments are illustrative in all respects and are not limiting. The scope of the present invention should be interpreted as including all modifications and variations derived from the meaning and scope of the claims below and their equivalent concepts rather than the above detailed description. [Sequence List Free Text]
[0159] SEQ ID NO: 1: Synthetic endolysin LNT101 SEQ ID NO: 2: Synthetic endolysin LNT101 coding gene SEQ ID NO: 3: Synthetic forward primer SEQ ID NO: 4: Synthetic reverse primer SEQ ID NO: 5: Synthetic PBPA90 genome SEQ ID NO: 6: Synthetic endolysin LNT102 SEQ ID NO: 7: Synthetic endolysin LNT102 coding gene SEQ ID NO: 8: Synthetic Cecropin A SEQ ID NO: 9: Synthetic Cecropin A coding gene SEQ ID NO: 10: Synthetic endolysin LNT103 SEQ ID NO: 11: Synthetic endolysin LNT103 coding gene SEQ ID NO: 12: Synthetic linker SEQ ID NO: 13: Synthetic fusion polypeptide CecA-LNT101 SEQ ID NO: 14: Synthetic fusion polypeptide CecA-LNT101 coding gene SEQ ID NO: 15: Synthetic fusion polypeptide LNT103 containing MAS, His tag and extra sequence SEQ ID NO: 16: Synthetic fusion polypeptide CecA-LNT101 containing MAS, His tag and extra sequences
Claims
1. A polypeptide having endolysin activity against gram-negative bacteria and comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:
6.
2. The polypeptide according to claim 1, wherein the Gram-negative bacterium is one or more species selected from the group consisting of Pseudomonas bacteria, Acinetobacter bacteria, Escherichia bacteria, Enterobacter bacteria, and Klebsiella bacteria.
3. A polynucleotide encoding the polypeptide of claim 1.
4. The polynucleotide of claim 3 comprising the nucleic acid sequence of SEQ ID NO:2 or SEQ ID NO:
7.
5. A recombinant vector comprising the polynucleotide of claim 3.
6. A recombinant cell comprising the polynucleotide of claim 3 or a recombinant vector comprising the same.
7. A bacteriophage comprising a polynucleotide encoding a polypeptide having endolysin activity against Gram-negative bacteria and comprising the amino acid sequence of SEQ ID NO:
1.
8. 8. The bacteriophage of claim 7, wherein the polynucleotide encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 comprises the nucleic acid sequence of SEQ ID NO:
2.
9. The bacteriophage according to claim 7 or 8, which has antibiotic activity against Pseudomonas bacteria.
10. Cecropin A, and Polypeptides having endolysin activity against gram-negative bacteria and comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 6 A fusion polypeptide comprising:
11. The fusion polypeptide of claim 10, wherein cecropin A comprises the amino acid sequence of SEQ ID NO:
8.
12. The fusion polypeptide according to claim 10, wherein the cecropin A and the polypeptide of SEQ ID NO: 1 or SEQ ID NO: 6 are linked in order from the N-terminus.
13. The fusion polypeptide of claim 10, wherein the cecropin A and the polypeptide of SEQ ID NO: 1 or SEQ ID NO: 6 are linked by a peptide linker.
14. The fusion polypeptide of claim 10 comprising the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:
13.
15. A polynucleotide encoding the fusion polypeptide according to any one of claims 10 to 14.
16. 16. The polynucleotide of claim 15 comprising the nucleic acid sequence of SEQ ID NO:11 or SEQ ID NO:
14.
17. A recombinant vector comprising the polynucleotide of claim 15.
18. A recombinant cell comprising the polynucleotide of claim 15 or a recombinant vector comprising the same.
19. A polypeptide according to claim 1, and The fusion polypeptide according to any one of claims 10 to 14. An antibiotic comprising one or more selected from the group consisting of:
20. 20. The antibiotic of claim 19, further comprising a polymyxin antibiotic.
21. 21. The antibiotic of claim 20, wherein the polymyxin antibiotic is polymyxin B, colistin, or a combination thereof.
22. The antibiotic according to claim 19, having antibiotic activity against gram-negative bacteria.
23. The antibiotic according to claim 22, wherein the Gram-negative bacterium is one or more species selected from the group consisting of Pseudomonas bacteria, Acinetobacter bacteria, Escherichia bacteria, Enterobacter bacteria, and Klebsiella bacteria.
24. The antibiotic according to claim 23, wherein the Pseudomonas bacterium is Pseudomonas aeruginosa, the Acinetobacter baumannii, the Escherichia bacterium is Escherichia coli, the Enterobacter bacterium is Enterobacter aerogenes, and the Klebsiella bacterium is Klebsiella pneumoniae.
25. The polypeptide of claim 1 . A fusion polypeptide according to any one of claims 10 to 14, a polynucleotide encoding the polypeptide; a polynucleotide encoding the fusion polypeptide; a recombinant vector comprising a polynucleotide encoding the polypeptide; A recombinant vector comprising a polynucleotide encoding the fusion polypeptide; and Recombinant cells containing the polynucleotide or recombinant vector A pharmaceutical composition for preventing or treating infection with a gram-negative bacterium or a disease caused by a gram-negative bacterium, comprising one or more selected from the group consisting of:
26. The pharmaceutical composition according to claim 25, wherein the Gram-negative bacterium is one or more selected from the group consisting of Pseudomonas, Acinetobacter, Escherichia, Enterobacter, and Klebsiella.
27. 27. The pharmaceutical composition according to claim 26, wherein the Pseudomonas bacterium is Pseudomonas aeruginosa, the Acinetobacter baumannii, the Escherichia bacterium is Escherichia coli, the Enterobacter bacterium is Enterobacter aerogenes, and the Klebsiella bacterium is Klebsiella pneumoniae.
28. The pharmaceutical composition of claim 26, wherein the gram-negative bacterium is a Pseudomonas bacterium, and the disease caused by a Pseudomonas bacterium is a skin infection, a bedsore, pneumonia, bacteremia, sepsis, endocarditis, meningitis, otitis externa, otitis media, keratitis, osteomyelitis, enteritis, peritonitis, or cystic fibrosis.
29. The pharmaceutical composition according to claim 26, wherein the Gram-negative bacterium is an Acinetobacter bacterium, and the disease caused by an Acinetobacter bacterium is a skin infection, pneumonia, bacteremia or septicemia.
30. The pharmaceutical composition according to claim 26, wherein the Gram-negative bacterium is an Escherichia bacterium, and the disease caused by the Escherichia bacterium is enteritis, Crohn's disease, ulcerative colitis, bacterial dysentery, urinary tract infection, skin infection, bacteremia or sepsis.
31. A feed additive comprising the antibiotic of claim 19.
32. A disinfectant comprising the antibiotic of claim 19.
33. A cleaning agent comprising the antibiotic of claim 19.
Citation Information
Patent Citations
Modified Peptides
JP2020500535A
